|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The diagnosis of WM is established by the presence of lymphoplasmacytic lymphoma in the bone marrow or other organs, a monoclonal IgM paraproteinemia and the recurrent MYD88 L265P somatic mutation.
|
31591468 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, in this small case series we showed that MYD88 L265P mutation analysis could serve as a useful adjunct in distinguishing benign from lymphomatous PE in patients with LPL.
|
31556196 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P is the most common mutation in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and one of the most frequent in poor-prognosis subtypes of diffuse large B-cell lymphoma (DLBCL).
|
31698464 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>Results</i>: MYD88 L265P mutations were detected in 22 of 29 samples from 14 patients with diffuse large B-cell lymphomas and one patient with lymphoplasmacytoid lymphoma.
|
31603365 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation.
|
30198568 |
2019 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Nine of these samples tested positive for MYD88 p.(L265P) (8 LPL and 1 PCNSL).
|
29210102 |
2018 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The recent surge in next generation sequencing (NGS) technology has shed more light on the genetic landscape of SBCLs through characterization of numerous driver mutations including SF3B1 and NOTCH1 in CLL, ATM and CCND1 in MCL, KMT2D and EPHA7 in FL, MYD88 (L265P) in LPL, KLF2 and NOTCH2 in splenic MZL (SMZL) and BRAF (V600E) in HCL.
|
27121112 |
2016 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identical clonal origin was confirmed by PCR for 21 LPL/WM cases and MYD88 L265P was detected in both B-cell and plasma cell fractions.
|
27890075 |
2016 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-IgM LPLs are a clinically and pathologically heterogeneous group and often harbor MYD88 L265P mutation, albeit at a lower rate than classic WM.
|
27329639 |
2016 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study confirms the strong association of the MYD88 L265P mutation with LPL, as well as the existence of rare cases of small B-cell lymphoma that complicate this association.
|
26230596 |
2015 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P was found in 49/51 (96%) LPL cases and in 1/13 (7·6%) MZL (splenic type), whereas all CLL samples remained negative.
|
25819228 |
2015 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The aim of our study was to establish an unlabeled probe genotyping approach for rapid detection of the MYD88 L265P mutation in the differential diagnosis of Waldenstrӧm macroglobulinemia patients.
|
25462104 |
2015 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
|
25216226 |
2015 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most distinguishing features of LPL with respect to MZL were focal paratrabecular involvement (P < .001), the presence of lymphoplasmacytoid cells (P < .001) and Dutcher bodies (P < .001), increased numbers of mast cells (P < .001), and the MYD88 L265P mutation (P < .001).
|
25972321 |
2015 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The absence of plasmacytoid cells, the presence of plasma cells predominantly outside the nodular lymphoid infiltrates, IGHV4-34 restriction and absence of MYD88 L265P mutation strongly suggest that cold agglutinin-associated lymphoproliferative disease is a distinct entity that is different from lymphoplasmacytic lymphoma.
|
24143001 |
2014 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An oncogenic gain-of-function mutation (L265P) in the human MYD88 gene has been found to be present in most cases of WM/LPL, yet is absent in most other cases of B-cell chronic lymphoproliferative disorders (LPD), including SMZL.
|
24842316 |
2014 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although not entirely specific, MYD88 L265P is a useful adjunct for bone marrow diagnosis in separating LPL from other small B-cell lymphomas and plasma cell myeloma.
|
23955458 |
2013 |
|
rs387907272
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating Waldenström's macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features.
|
22931316 |
2012 |
|
rs116446171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conduct a two-stage genome-wide association study of WM/LPL in 530 unrelated cases and 4362 controls of European ancestry and identify two high-risk loci associated with WM/LPL at 6p25.3 (rs116446171, near EXOC2 and IRF4; OR = 21.14, 95% CI: 14.40-31.03, P = 1.36 × 10<sup>-54</sup>) and 14q32.13 (rs117410836, near TCL1; OR = 4.90, 95% CI: 3.45-6.96, P = 8.75 × 10<sup>-19</sup>).
|
30305637 |
2018 |
|
rs117410836
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We conduct a two-stage genome-wide association study of WM/LPL in 530 unrelated cases and 4362 controls of European ancestry and identify two high-risk loci associated with WM/LPL at 6p25.3 (rs116446171, near EXOC2 and IRF4; OR = 21.14, 95% CI: 14.40-31.03, P = 1.36 × 10<sup>-54</sup>) and 14q32.13 (rs117410836, near TCL1; OR = 4.90, 95% CI: 3.45-6.96, P = 8.75 × 10<sup>-19</sup>).
|
30305637 |
2018 |
|
rs113488022
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The recent surge in next generation sequencing (NGS) technology has shed more light on the genetic landscape of SBCLs through characterization of numerous driver mutations including SF3B1 and NOTCH1 in CLL, ATM and CCND1 in MCL, KMT2D and EPHA7 in FL, MYD88 (L265P) in LPL, KLF2 and NOTCH2 in splenic MZL (SMZL) and BRAF (V600E) in HCL.
|
27121112 |
2016 |
|
rs121913377
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The recent surge in next generation sequencing (NGS) technology has shed more light on the genetic landscape of SBCLs through characterization of numerous driver mutations including SF3B1 and NOTCH1 in CLL, ATM and CCND1 in MCL, KMT2D and EPHA7 in FL, MYD88 (L265P) in LPL, KLF2 and NOTCH2 in splenic MZL (SMZL) and BRAF (V600E) in HCL.
|
27121112 |
2016 |
|
rs1392080411
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The recent surge in next generation sequencing (NGS) technology has shed more light on the genetic landscape of SBCLs through characterization of numerous driver mutations including SF3B1 and NOTCH1 in CLL, ATM and CCND1 in MCL, KMT2D and EPHA7 in FL, MYD88 (L265P) in LPL, KLF2 and NOTCH2 in splenic MZL (SMZL) and BRAF (V600E) in HCL.
|
27121112 |
2016 |
|
rs104893626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We screened 418 patients with B-cell lymphoproliferative disorders and described the presence of the C1013G/CXCR4 warts, hypogammaglobulinemia, infections, and myelokathexis-associated mutation in 28.2% (37/131) of patients with lymphoplasmacytic lymphoma (Waldenström macroglobulinemia [WM]), being either absent or present in only 7% of other B-cell lymphomas.
|
24711662 |
2014 |
|
rs1472503583
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The absence of plasmacytoid cells, the presence of plasma cells predominantly outside the nodular lymphoid infiltrates, IGHV4-34 restriction and absence of MYD88 L265P mutation strongly suggest that cold agglutinin-associated lymphoproliferative disease is a distinct entity that is different from lymphoplasmacytic lymphoma.
|
24143001 |
2014 |